Sarepta Therapeutics | SRPT - Current Assets


Sarepta Therapeutics reported $2.72B in Current Assets for its fiscal quarter ending in September of 2025.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.08B 115.87M Sep/2025
Agios Pharmaceuticals USD 1.03B 13.64M Sep/2025
Alnylam Pharmaceuticals USD 3.95B 309.11M Sep/2025
Amgen USD 27.88B 1.15B Sep/2025
Biogen USD 8.94B 968.9M Sep/2025
BioMarin Pharmaceutical USD 3.85B 49.21M Sep/2025
Daiichi Sankyo JPY 2.1T 218.5B Dec/2025
Eli Lilly USD 62.07B 12.22B Sep/2025
Gilead Sciences USD 18.84B 4.12B Sep/2025
Incyte USD 4.28B 634.19M Sep/2025
Insmed USD 1.93B 149.77M Sep/2025
Ionis Pharmaceuticals USD 2.52B 58.16M Sep/2025
Moderna USD 6.6B 427M Sep/2025
Neurocrine Biosciences USD 2.16B 409.5M Sep/2025
Pfizer USD 46.92B 3.22B Sep/2025
PTC Therapeutics USD 2.01B 265.07M Sep/2025
Regeneron Pharmaceuticals USD 17.98B 1.12B Sep/2025
Roche Holding CHF 38.73B 3.03B Dec/2025
Sanofi EUR 30.95B 3.09B Dec/2025
Sarepta Therapeutics USD 2.72B 65.32M Sep/2025
Tectonic Therapeutic USD 273.24M 17.61M Sep/2025
Ultragenyx Pharmaceutical USD 643.21M 76.58M Sep/2025
Vertex Pharmaceuticals USD 10.57B 141.7M Sep/2025